Public submissions on scheduling matters referred to the ACMS #22, ACCS #21 and Joint ACMS-ACCS #17 meetings held in November 2017

Public submissions made in response to:

• the delegates' proposed amendments to the Poisons Standard published on 6 September 2017; and
• the delegates' interim decision published on 5 February 2018.

Public submissions on proposed amendments

• Public submissions on scheduling proposals referred to the November 2017 meeting of the ACMS #22 - Part 1 (pdf,3.7Mb)
• Public submissions on scheduling proposals referred to the November 2017 meeting of the ACMS #22 - Part 2 (pdf,1.5Mb)
• Public submissions on scheduling proposals referred to the November 2017 meetings of the ACCS #21 and Joint ACMS-ACCS #17 (pdf,2.3Mb)

Public submissions on the interim decisions

Public submissions made in response to the Secretary's interim decisions relating to scheduling proposals referred to the November 2017 meeting of the ACMS #22.

Hyaluronic acid

1. Consultation submission: Sanofi (pdf,79kb)
2. Consultation submission: Individual - The submitter did not give permission to publish their name or submission.
3. Consultation submission: Individual - The submitter did not give permission to publish their name or submission.

Cardarine

No public submissions were received.

Stenabolic

No public submissions were received.

Ibutamoren

No public submissions were received.

Consultation submission: Alpha-PVP and related substances (cathinones & methylone)

No public submissions were received.

Ibuprofen

1. Consultation submission: Individual - The submitter did not give permission to publish their name or submission.
2. Consultation submission: Ron Batagol and Gregory Peterson (pdf,153kb)
3. Consultation submission: Pharmaceutical Society of Australia (PSA) (pdf,265kb)
4. Consultation submission: Painaustralia (pdf,1.07Mb)*
5. Consultation submission: Reckitt Benckiser (pdf,406kb)
6. Consultation submission: Australian Self Medication Industry (ASMI) (pdf,318kb)

Melanotan II

1. Consultation submission: NSW Poisons Information Centre (pdf,237kb)

Orphenadrine combined with paracetamol

No public submissions were received.

Clotrimazole

1. Consultation submission: Australian Self Medication Industry (ASMI) (pdf,318kb)

Public submissions made in response to the Secretary’s interim decisions relating to scheduling proposals referred to the November 2017 meeting of the Joint ACMS-ACCS #17

Helium

1. Consultation submission: John Manfred, National Production Manager, Air Liquide Australia Limited - The submitter did not give permission to publish their submission.
2. Consultation submission: Individual - The submitter did not give permission to publish their name or submission.
3. Consultation submission: Kathryn Walton, Executive Officer, Australian New Zealand and Industrial Gas Association - The submitter did not give permission to publish their submission.

Salts of boric acid

1. Consultation submission: Accord (pdf,234kb)
2. Consultation submission: Australian Self Medication Industry (ASMI) (pdf,318kb)

Polihexanide

1. Consultation submission: Accord (pdf,234kb)
2. Consultation submission: Australian Self Medication Industry (ASMI) (pdf,318kb)

Cimicoxib

No public submissions were received.

Public submissions made in response to the Secretary’s interim decisions relating to scheduling proposals referred to the November 2017 meeting of the ACCS #21

Fluralaner

1. Individual - The submitter did not give permission to publish their name or submission.

Metofluthrin

No public submissions were received.

Alpha-cypermethrin

No public submissions were received.

Silver Oxide

1. Consultation submission: Accord (pdf,234kb)

1-Deoxy-1-(methylamino)-D-glucitol N-C10- 16 acyl derivatives

1. Consultation submission: Accord (pdf,234kb)
2. Consultation submission: Australian Self Medication Industry (ASMI) (pdf,318kb)

Phenyl methyl pyrazolone

1. Consultation submission: Accord (pdf,234kb)
2. Consultation submission: Australian Self Medication Industry (ASMI) (pdf,318kb)

Dinotefuran

No public submissions were received.

Afidopyropen

No public submissions were received.